Patents Assigned to Merck
  • Materials for electronic devices
    Patent number: 10529930
    Abstract: Compounds of formula (1) that have functional substituents in a specific spatial arrangement, and electronic devices that include a compound of formula (1), and to the preparation of compounds of formula (1).
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: January 7, 2020
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Irina Martynova, Anja Jatsch, Thomas Eberle, Jonas Valentin Kroeber, Christof Pflumm
  • Bicyclic heterocyclic derivatives
    Patent number: 10526325
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 7, 2020
    Assignee: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Fused heteroaryl derivatives as orexin receptor antagonists
    Patent number: 10526336
    Abstract: The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 7, 2020
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Douglas C. Beshore, Na Meng, Yunfu Luo
  • COMPOUNDS CONTAINING SI ATOMS FOR OPTICALLY ACTIVE DEVICES
    Publication number: 20200002363
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
    Type: Application
    Filed: February 14, 2018
    Publication date: January 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Lars DOBELMANN-MARA, Stefan RIEDMUELLER, Martin SCHRAUB
  • HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
    Publication number: 20200002304
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
    Type: Application
    Filed: February 14, 2018
    Publication date: January 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Lars DOBELMANN-MARA, Stefan RIEDMUELLER, Martin SCHRAUB
  • SPIROBIFLUORENE COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES
    Publication number: 20200006665
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Elvira Montenegro, Amir Hossain Parham, Philipp Stoessel, Teresa Mujica-Fernaud, Frank Voges, Arne Buesing
  • ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20200002407
    Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
    Type: Application
    Filed: June 7, 2019
    Publication date: January 2, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: KALPIT A. VORA, KARA S. COX, AIMIN TANG, ZHIFENG CHEN, DANIEL DISTEFANO, LAN ZHANG, HUA-POO SU
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS
    Publication number: 20200002424
    Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.
    Type: Application
    Filed: August 15, 2019
    Publication date: January 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Ilhan CELIK, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
  • MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES
    Publication number: 20200006657
    Abstract: The present invention relates to a process to produce compounds of the formula (1) which are suitable for use in electronic devices, as well as to intermediate compounds of formula (Int-1) and compounds of formula (1-1) and (1-2) obtained via the process. These compounds are particularly suitable for use organic electroluminescent devices. The present invention also relate to electronic devices, which comprise these compounds.
    Type: Application
    Filed: September 6, 2019
    Publication date: January 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Frank Voges, Teresa MUJICA-FERNAUD, Elvira MONTENEGRO
  • Liquid-crystal medium
    Patent number: 10519375
    Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1 and R1* each, independently of one another, denote an alkyl or alkoxy radical having 1 to 15 C atoms, where, in addition, one or more CH2 groups in these radicals may each be replaced, independently of one another, by in such a way that O atoms are not linked directly to one another, and in which, in addition, one or more H atoms may be replaced by halogen, A1 denotes L1 denotes F, Cl, CF3, OCF3 or CHF2, and to the use thereof for electro-optical purposes, in particular for shutter glasses, 3D applications, in TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, PS-FFS and PS-VA-IPS displays.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: December 31, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Helmut Haensel, Andreas Pohle, Brigitte Schuler, Christian Jasper
  • Removal of fragments from a sample containing a target protein using activated carbon
    Patent number: 10519194
    Abstract: The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal, of protein, fragments without adversely affecting the yield of the desired protein product.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventors: Mikhail Kozlov, Matthew T. Stone, Romas Skudas, Kevin Galipeau
  • Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
    Patent number: 10519147
    Abstract: Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: December 31, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas J. Greshock, James Mulhearn, Liangqin Guo, Ting Zhang, Deping Wang, Ronald M. Kim, Mark E. Layton, Michael J. Kelly, III, Rajan Anand, Philippe Nantermet, Tianying Jian, Anthony J. Roecker, Walter Won, Gang Zhou
  • Antidiabetic tricyclic compounds
    Patent number: 10519115
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 31, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Purakkattle Biju, Steven L. Colletti, Qun Dang, Pawan Dhondi, Candido Gude, Hubert Josien, Nam Fung Kar, Anilkumar G. Nair, Ravi P. Nargund, De-Yi Yang, Cheng Zhu
  • Pyridazinone macrocycles as IRAK inhibitors and uses thereof
    Patent number: 10517872
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos
  • Spectrophotometer and method for carrying out a spectrophotometric measurement
    Patent number: 10520358
    Abstract: The present invention relates to a spectrophotometer comprising a light source; and a light sensor for measuring the light emitted by the light source and passing through or reflected a sample; and being characterized by an offset generator for applying an offset value to an output of the light sensor. The invention further relates to a method for performing a related spectrophotometric measurement.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventor: Bernhard Guennewig
  • Antiviral aliphatic ester prodrugs of tenofovir
    Patent number: 10519159
    Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: December 31, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals, LLC.
    Inventors: Jean-Laurent Paparin, Izzat Raheem, Houcine Rahali, Daniel Da Costa, David Dukhan
  • DRUG DELIVERY SYSTEM FOR THE DELIVERY OF ANTIVIRAL AGENTS
    Publication number: 20190388590
    Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: May 8, 2017
    Publication date: December 26, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephanie Elizabeth Barrett, Marian E. Gindy, Li Li, Ryan S. Teller, Seth P. Forster
  • COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
    Publication number: 20190389827
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
    Type: Application
    Filed: February 14, 2018
    Publication date: December 26, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Lars DOBELMANN-MARA, Stefan RIEDMUELLER, Martin SCHRAUB
  • Drug Delivery System for the Delivery of Antiviral Agents
    Publication number: 20190388336
    Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 26, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Stephanie Elizabeth Barrett, Marian E. Gindy, Li Li, Seth P. Forster, Ryan S. Teller
  • Compounds for Optically Active Devices
    Publication number: 20190389829
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.
    Type: Application
    Filed: September 4, 2019
    Publication date: December 26, 2019
    Applicant: Merck Patent GmbH
    Inventors: Lars Dobelmann-Mara, Stefan Riedmueller, Martin Schraub